A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer-Reference-Cited by-同舟云学术

A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer

Published:1987-08 Issue:8 Volume:23 Page:1155-1162
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Spittle Margaret F,Hill Bridget T,Ostrowski M.J,Macrae K.D,Bates Thelma D,Martin W.M.C,Nicol N.T,Edelstyn G.A

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Comparison of 5-day, 1-day and 2-day cyclical combination chemotherapy in advanced breast cancer;Edelstyn;Lancet,1975

2. Comparison of 5-day and 2-day cyclical combination chemotherapy in advanced breast cancer;Edelstyn;Clin Oncol,1979

3. Adjuvant chemotherapy in the treatment of breast cancer: results of a multicentre study;Spittle;Eur J Surg Oncol,1986

4. Short course cyclical chemotherapy in advanced breast cancer;Edelstyn;Lancet,1977

5. Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma and other tumours;Smith;Cancer Treat Rep,1978

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer;JNCI: Journal of the National Cancer Institute;2008-12

2. Phase III Study of Standard Combination Versus Rotating Regimen of Induction Chemotherapy in Patients With Hormone Insensitive Metastatic Breast Cancer;American Journal of Clinical Oncology;2007-04

3. A Systematic Overview of Chemotherapy Effects in Breast Cancer;Acta Oncologica;2001-03-01

4. Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85);British Journal of Cancer;1997-08

5. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma;Clinical Oncology;1993-01